NEW YORK (GenomeWeb News) – Cell Signaling Technology today said that Bristol-Myers Squibb will use its PhosphoScan technology in cell and tumor phospho-profiling of a small molecule kinase inhibitor.
 
The PhosphoScan process involves immunoaffinity purification and tandem mass spectrometry. It will be applied to in vivo phosphorylation profiling of kinase inhibitor response profiles in xenograft tumor models.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.